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Introduction
The pathology of malignant lymphoma remains a rapidly
evolving field. Based on the long tradition of research into
the understanding of the biology of the tumor cells that
leads to better definition for clinicopathologic entities,
resulting in new methods used by pathologists to diagnose
a lymphoma, also in the first 4 months of 2008 a large
series of papers was published. In this overview, the most
important of these are described shortly.
Biology of lymphoma
Hodgkin lymphoma
Hodgkin lymphoma (HL) remains an elusive disease. Liu et
al. described the involvement of defects in deoxyribonu-
cleic acid repair in six out of eight cell lines and three out
seven cases, with deletions and insertions in the RaD3-
related (ATR) genes and suggest that these might prevent
repair induced by oxidative stress of the inflammatory
infiltrate in HL, thereby once again pointing to the
inflammation as an important driving force of the disease
[1]. Diepstra et al. showed that the tumor cells in about half
of the HL cases express human leukocyte antigen G, which
inhibits cytotoxicity. This expression was associated with
loss of major histocompatibility complex class I so that by
these mechanisms, Hodgkin cells protect themselves from
killing by the inflammatory response [2].
Using cell lines from HL and anaplastic large cell
lymphoma (ALCL), Hirsch et al. showed that Hodgkin
cells are unresponsive for CD30 signaling but that in ALCL
cells, CD30 stimulation causes major transcriptional alter-
ations, including activation of caspases and nuclear factor-
kappaB-mediated survival, in fact competing processes [3].
Microribonucleic acid (miRNA) expression profiling in
classic HL (cHL) revealed that the expression of 157
miRNAs in lymph nodes from 49 cHL patients and ten
reactive lymph nodes separated three well-defined groups:
nodular sclerosis cHL, mixed cellularity cHL, and reactive
lymph nodes. The results were confirmed in a separate
series of cases and cell lines. These findings suggest that
miRNAs play an important role in the biology of cHL [4].
Using mass spectrometry, Ma et al. detected in cells and
supernatants of HL cell lines in total 1,290 proteins,
including 368 secreted proteins. The secreted proteins
included 37 related to immune response. Several of these
proteins were also elevated in the serum of patients with HL
and may serve as biomarkers after confirmatory studies [5].
All these findings lead to a better understanding of what
is happening in HL importantly, since still about 10–15% of
the patients eventually die of this lymphoma type.
B cell lymphomas
It is now widely accepted that diffuse large B cell
lymphoma consists of at least two phenotypic subtypes,
that is, the germinal center B cell-like and the activated B
cell-like groups. It has been shown that the former group
responds favorably to chemotherapy and expresses high
levels of BCL6. But, the latter group has lower levels of
BCL6, constitutively activated nuclear factor-kappaB, and
tends to be refractory to chemotherapy. Ding et al. showed
that the STAT3 gene is a transcriptional target of BCL6. As
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a result, high-level STAT3 expression and activation are
preferentially detected in the activated B cell group and
BCL6-negative normal germinal center B cells [6].
The unusual-type pyothorax-associated lymphoma is a B
cell lymphoma developing in the pleural cavity affected by
chronic pyothorax. Takakuwa et al. showed by clonality
testing and sequencing of the immunoglobulin heavy chain
gene in cases and cell lines that this tumor is derived from
crippled postgerminal center cells. Usually, such cells do
not survive, but the authors suggest that the Epstein–Barr
virus (EBV) that is invariably present in these cases might
provide the basis for the cell survival [7]. O’Hara et al.
detected in this lymphoma type that in addition, specific
miRNA gene amplifications and concordant changes in pre-
miRNA and mature miRNA were present [8].
By clonality analysis and sequencing of the variable
region of the immunoglobulin gene in cases of thyroid
lymphoma proceeded by Hashimoto thyroiditis showed that
most cases had already rearranged the immunoglobulin
gene of the malignant population in the benign precursor
lesion, supporting the notion that these lymphomas indeed
develop out of the Hashimoto’s thyreoiditis [9].
Montesinos et al. used expression profiling to determine
the cell of origin of 21 cases of central nervous diffuse large
B cell lymphoma and compared the results with profiles
from various subsets of normal B cells. The expression
profile of the central nervous lymphomas was similar to
that of late germinal center B cells, and some were of the
activated B cell-like diffuse large B cell lymphoma from
other sites and others from the germinal center B cell-like
subtype [10].
T-cell lymphoma
Kchour et al. showed in an extensive study on 20 patients
with human T lymphotropic virus (HTLV1)-associated T
cell lymphoma/leukemia that, as compared to organs from
matched controls, increased vascularization was present in
all tested involved organs from adult T cell leukemia/
lymphoma (ATLL) patients, suggesting that angiogenesis
plays an important role in the development or organ
invasion of ATLL and could represent a potentially
interesting target for antiangiogenic therapy of ATLL [11].
Epidemiology of lymphoma
It is well known that regional differences exist in the
epidemiology of lymphoma types. Using the World Health
Organization (WHO) classification on 2,260 lymphomas
from Japan, Aoki et al. confirmed that follicular lymphoma
is rare (18%) compared to that of the Western series but that
T/natural killer (NK) cells are quite common (25%). Like in
Western counties, diffuse large B cell lymphoma is the most
common type (33%). Even within Japan, there are regional
differences with some areas with high numbers of HTLV1-
associated lymphoma proliferations [12].
A study of 61 Korean cases of follicular lymphoma
showed that this type is not only relatively rare in Eastern
countries but also that it is more often grade 3 (57%) and
has less often a t(14;18), namely 44%. Since the cases of
grade 3 had the least translocations, it might be that they
correspond to the 3B cases in Western countries [13].
Changing the environment may well lead to changes in
frequencies of malignancies. Chang et al. show that in 74
cases of HL diagnosed before 1996, EBV was present in
61% but in 99 more recent cases, 39%; the recent cases
were also more often of the nodular sclerosing type
compared to earlier. The pattern therefore moves toward a
more Western one [14].
Defining entities
B cell lymphomas
Knowledge of the state of differentiation of lymphoma cells
is very helpful in classification. Germinal center B cell-
expressed transcript-1 gene that codes for a serpin expressed
in the germinal center (centerin) was characterized in human
tissues, cell lines, and a large series of lymphomas. The
results demonstrate that centerin is expressed exclusively by
neoplasms hypothetically to be arrested at the germinal
center stage of differentiation, including follicular lympho-
ma, nodular lymphocyte-predominant HL, and a subset of
diffuse large B cell lymphoma, T cell/histiocyte-rich B cell
lymphoma, and Burkitt lymphoma. Chronic lymphocytic
leukemia, splenic marginal zone lymphoma, and mantle cell
lymphoma are negative; it would be interesting to know the
results in marginal zone lymphomas, the lymphoma type that
is presently often misdiagnosed (see below) [15].
A proportion of gastric extranodal marginal zone B cell
lymphomas of the mucosa-associated lymphoid tissue
(MALT) type are dependent on the presence of H. pylori
Toll-like receptors that recognize bacterial proteins and
autoantigens, which results in inflammatory reactions and
influences tumor development and growth. Adam et al.
investigated the presence of Toll-like receptors 4, 5, and 9
on a series of lymphomas and found TLL-4 to be expressed
only on all 19 extranodal marginal zone lymphomas. It is a
pity that no data on t(11;18), associated with unresponsive-
ness for H. pylori eradication, are given [16].
It is quite clear that there is a strong relation between
cyclin D1 overexpression and mantle cell lymphoma but
also that there are cyclin D1-negative mantle cell lympho-
ma and cyclin D1-positive malignancies of lymphoid
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lineage (hairy cell leukemia, plasmacytoma) that may
express cyclin D1. Ehringer et al. investigated 231 diffuse
large B cell lymphomas for the expression of cyclin D1 and
CD5 and found ten cyclin D1-positive and CD5-negative
cases. Two of these cases had t(11;14) by fluorescent in situ
hybridization, and two cases had amplification of the cyclin
D1 signal. The expression of MUM1 and bcl-6 in nine of
ten cases confirms that these are not CD5-blastoid mantle
cell lymphoma. These data underscore the importance of
combining morphology, immunophenortype, and molecular
findings in order to reach a correct classification [17].
Brizova showed in a large series of cases that the
messenger RNA level of cyclin D1 in 60 of 61 mantle cell
lymphoma far exceeds that of other lymphoma types except
for mucosa-associated lymphomas. The latter finding was
attributed to the presence of epithelial cells in the tested
sample. The study did not contain cases of highly cyclin
D1-expressing plasmacytomas. It was not clear from the
paper that the quantitative reverse transcriptase polymerase
chain reaction (PCR) method was superior to immunostain-
ing for cyclin D1 [18].
Using expression profiling, the existence of cyclin D1-
negative mantle cell lymphomas was discovered, but these are
very difficult to recognize (Fu et al.). Ek et al. described that
the transcription factor Sox11 is specifically expressed in the
nucleus of mantle cell lymphoma and not in other lymphomas
and benign lymphoid tissue. Although the role of Sox11
presently is not known in lymphocyte ontogeny, it is normally
expressed in the developing central nervous system in the
embryo and shows sequence homology with Sox4, a
transcription factor crucial for B lymphopoiesis. If confirmed,
this may be an important marker for detecting mantle cell
lymphoma, especially cyclin D1-negative cases [19].
The topic of Burkitt and Burkitt-like lymphoma is very
hot, and an important one at the European Association of
Hematopathology meeting in Bordeaux. There are also
several papers that contribute to our knowledge, even
though a solution how to diagnose these cases is not yet
available.
Chuang et al. describe the pheno- and genotypic profile
of 17 sporadic pediatric and 14 adult Burkitt lymphoma and
showed, as expected, large similarities. The prognosis,
however, is very different, with good prognosis in the
pediatric age group and poor prognosis in adults. The
authors suggest that this is partially due to an initial wrong
diagnosis but mainly due to insufficient treatment. This
point warrants further studies [20].
In 72 patients with lymphomas that had Burkitt or
Burkitt-like morphology, Nomura et al. analyzed pheno-
typic and clinical factors and showed that these patients
benefit from aggressive short-term therapy, regardless of
the presence of the typical Burkitt phenotype (bcl-2−;
CD10+; mib 1 >95%) c-myc translocation [21].
Rodig et al. based on the recently described gene
expression profiles differentiating B cell lymphoma and
diffuse large B cell lymphoma examined a cohort of 67
cytogenetically defined aggressive lymphomas using im-
munohistochemical techniques for expression of TCL1,
CD38, and CD44 and found distinct expression patterns
between MYC+ and MYC− tumors that are better pre-
dictors of MYC status than combined staining for CD10
and BCL2 [22].
T cell lymphomas
The debate whether ALCL consist of two groups namely,
anaplastic lymphoma kinase (ALK)-positive and ALK-
negative, cases may be solved by the results of Salaverria
et al., since they found clear differences in the respective
genomic profiles of these groups, even though there were
few specific gene alterations for each group except for the
known translocations involving the ALK locus [23].
T/NK cell lymphomas of nasal type are relatively
common in Eastern Asia, and it probably is understandable
that a series of such cases that occur primarily in lymph
nodes was described from Japan. Takahashi collected a
series of EBV- and CR56-positive cases of such and
compare them with peripheral EBV-positive cytotoxic
peripheral T cell lymphomas NOS and primary nasal T/
NK lymphomas with secondary nodal involvement. Where-
as the nasal cases did not have clonally rearranged T cell
receptors, four of six nodal cases had a clonal T cell
receptor gamma rearrangement and all the T cell lympho-
mas. With respect to clinical features, they were only minor
differences between the groups. These results reiterate the
difficulties there still are in classifying T cell lymphomas in
a meaningful way [24].
EBV-associated T/NK-cell lymphoproliferative disorder
(EBV-T/NK LPD) of children and young adults is generally
referred to as severe chronic active EBV infection
(CAEBV). This disease is rare, associated with high
morbidity and mortality, and appears to be more prevalent in
East Asian countries. But, because there is no grading or
categorization system for CAEBV, pathologists and clinicians
often disagree regarding diagnosis and therapy. EBV-T/NK
LPD includes polyclonal, oligoclonal, and monoclonal
proliferation of cytotoxic T and/or NK cells. Moreover, a
unique disease previously described as infantile fulminant
EBV-associated T-LPD has been identified and overlaps with
EBV-T/NK LPD. Oshima et al. propose a clinicopathologic
categorization of EBV-T/NK: (1) category A1, polymorphic
LPD without clonal proliferation of EBV-infected cells, (2)
category A2, polymorphic LPD with clonality, (3) category
A3, monomorphic LPD (T cell or NK cell lymphoma/
leukemia) with clonality, and (4) category B, monomorphic
LPD (T cell lymphoma) with clonality and fulminant course.
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Categories A1, A2, and A3 possibly constitute a continuous
spectrum and together are equivalent to CAEBV. Category B
is the exact equivalent of infantile fulminant EBV-associated
T-LPD [25].
Shimauchi et al. hypothesized that adult T cell leukemia/
lymphoma derives from regulatory T cells since they
express CD4 and CD25. They show that these cases also
express the regulatory T cell marker FoxP3, but functional
studies revealed that the cells had no suppressor activity
toward CD8 cells. This study is important since in general,
phenotype is considered sufficient proof of derivation of a
lymphoma from a physiological cell, but the point that
phenotype and function go not always together needs to be
well taken [26].
Cutaneous lymphomas
The classification of cutaneous lymphomas remains a
difficult area. Khamaysi et al. applied the WHO–EORTC
classification on their series of cutaneous lymphomas and
found 43 new nonmycosis fungoides/Sezary syndrome
lymphomas; 29 B cell lymphomas of which 14 were
follicle center lymphoma, 10 marginal zone lymphoma, 4
diffuse large-B cell lymphoma, leg type, and 1 diffuse large
B cell lymphoma, other;14 T cell lymphomas including five
cases of lymphomatoid papulosis, two CD30+ anaplastic
large cell lymphomas, one NK/T cell lymphoma, and six
peripheral T cell lymphomas, unspecified. Of the six
“unspecified” T cell lymphomas, three were CD4+ small/
medium-sized pleomorphic T cell lymphoma, which is
considered currently a provisional entity under the unspec-
ified T cell category. The remaining three cases could not
be classified beyond the unspecified T cell category, of
which two cases had an aggressive course. They conclude
that the new WHO–EORTC classification is applicable to
most nonmycosis fungoides/Sezary syndrome primary
cerebral lymphoma cases, especially the B cell lymphomas
[27].
From their large collection of cutaneous lymphomas, the
EORTC cutaneous lymphoma group described their cases
of subcutaneous panniculitis-like T cell lymphoma in a
landmark paper. This lymphoma type is quite aggressive
and consists of cases of the alpha/beta T cell phenotype
(SPTL-AB) and with a gamma–delta T cell phenotype
(SPTL-GD). The series of 63 SPTL-ABs and 20 SPTL-
GDs were studied at a workshop of the EORTC Cutaneous
Lymphoma Group. SPTL-ABs were generally confined to
the subcutis, had a CD4−, CD8+, CD56-, betaF1+
phenotype, were uncommonly associated with a hemopha-
gocytic syndrome (HPS; 17%), and had a favorable
prognosis (5-year overall survival). SPTL-AB patients
without HPS had a significantly better survival than
patients with HPS. SPTL-GDs often showed (epi)dermal
involvement and/or ulceration, a CD4−, CD8−, CD56+/−,
betaF1-T cell phenotype, and poor prognosis, irrespective
of the presence of HPS or type of treatment. These results
indicate that SPTL-AB and SPTL-GD are distinct entities
and justify that the term SPTL should further be used only
for SPTL-AB. SPTL-ABs without associated HPS have an
excellent prognosis, and multiagent chemotherapy as the
first choice of treatment should be questioned [28].
Wasco et al. described the expression of MUM1 in a
series of 58 lymphomas presenting in the skin. It appeared
that CD30-positive lymphoproliferations, primary or sec-
ondary, generally express MUM1. Also, mycosis fungoides
with CD30-positive component expresses MUM1, but other
cases of mycosis fungoides were not [29].
The morphologic spectrum of 66 biopsies from 47
patients with primary cutaneous anaplastic large T cell
lymphoma appeared to be very large. The ‘common
variant’ was the most frequent (40%). Marked reactive
infiltrates are commonly present, and 26 cases were
classified as ‘inflammatory type’ (15 cases) or ‘lymphohis-
tiocytic’ (11 cases). Concerning the predominant cell
morphology, large anaplastic cells (33%) were almost as
frequent as large pleomorphic (36%) and small- to medium-
sized cells (26%). There were two rare cases with the
predominance of large cells with a ‘signet-ring’-like appear-
ance. Epidermotropism and the presence of eosinophils were
found in a proportion of cases in all variants [30].
New entities/subtypes
In this time of tailored therapy and multiple techniques, it
seems that each patient has his or her own specific subtype
of lymphoma. Prof. Lennert advocated that an entity could
be accepted as such if its incidence was at least 5% of the
lymphomas. This is probably too restricted as exemplified
by the subdivision in cutaneous large cell lymphoma in leg
type with poor prognosis and follicle center lymphoma with
a very good prognosis as proposed by the group of
Willemze. This subdivision was debated fiercely but is
now generally accepted. Van Galen of the Willemze group
now shows that expression profiling separates these sub-
groups into the leg type with intense cellular cytotoxic
response and the primary cutaneous follicle center lympho-
ma with constitutive activation of the intrinsic-mediated
apoptosis pathway, with concomitant downstream inhibi-
tion of this apoptosis pathway [31].
The spleen remains an enigmatic organ and so are the
lymphomas with primarily splenic involvement. Traverse et
al. described 37 cases selected from a group a patients with
circulating villous lymphocytes that have numerous baso-
philic villous lymphocytes. The patients, predominantly
older men, presented with moderate lymphocytosis and
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splenomegaly without pancytopenia. The monoclonal B
cells expressed IgM+D, IgM+G, IgM or IgG, as well as
CD76 and CD11c, frequently CD103, and rarely CD123.
Spleen sections were peculiar, with atrophic white pulp and
a monomorphic diffuse lymphoma infiltration in a con-
gested red pulp. Bone marrow infiltration was interstitial and
intrasinusoidal without extensive fibrosis. Cytogenetic anal-
ysis showed a frequent absence of clonal aberrations (68%).
Most cases (79%) were IgH-mutated, with an overrepresen-
tation of V(H)3 and V(H)4 gene families. These results, as
well as the clinical evolution, show that those lymphoma
cases represent a homogeneous group distinct from splenic
marginal zone lymphoma and reminiscent of hairy cell
leukemia variant, perhaps corresponding to a separate
lymphoma entity [32].
In a series of 55 cases of nodular predominant HL, Yang et
al. described a subset of cases that occur in older individuals,
at atypical sites and with an increased number of large cells.
It remains to be seen what the outcome of the cases is [33].
Vega et al. described six lymphoma cases characterized
by t(8;13), a translocation well known from the 8p11
myeloproliferative syndrome, a rare hematologic malignan-
cy characterized by myeloid hyperplasia, eosinophilia, and
precursor lymphoblastic lymphoma. Histologically, each tu-
mor was composed of two distinct cellular components: small-
to medium-sized T cells with scant cytoplasm that resembled
lymphoblasts and larger immature-appearing cells with more
abundant eosinophilic cytoplasm that resembledmyeloblasts, a
subset of which expressed myeloid antigens. In all cases, the
latter component tended to surround residual lymphoid
follicles and/or blood vessels. Numerous eosinophils and
prominent high endothelial venules were present in all of the
lymph node specimens. Interestingly, cells of both components
expressed CD3 on immunohistochemical stains [34].
Pitfalls in lymphoma diagnosis
Clonality does not equal malignancy. Germinal centers consist
of one to four clones of B cells, and thus clonality assessment
leads to oligo- or even monoclonal results. However, the
presence of light-chain-restricted plasma cells is unusual in a
germinal center. Nam-Cha et al. described eight such cases,
two of which were Castleman’s disease. As expected, a clonal
peak was found at clonality testing in most of these cases. One
patient developed a follicular lymphoma, so that at present,
the meaning of the finding remains unclear, but certainly,
clonality is not sufficient to diagnose lymphoma [35].
Nodal marginal zone lymphoma is a recognized difficult
entity, especially since there is no specific diagnostic
marker. Especially challenging are cases with prominent
follicular colonization. Naresh described 15 such cases,
almost all referral cases and all with a different initial
diagnosis. One can only recognize these cases if the
immunophenotype of the cells follicle centers is assessed
with great care. Benign follicle center cells express CD10
and Bcl-6 but not Bcl-2 and MUM1. In contrast, the
colonizing marginal zone lymphoma cells express Bcl-2
and often MUM1 but not Bcl-6 and CD10. Partially colo-
nized follicles showed a ‘moth-eaten’ appearance on CD10,
Bcl-2, Bcl-6, and MUM1 immunohistochemistry [36].
Increasingly, bone marrow biopsies are taken with
rituximab treatment to evaluate the treatment response.
Regularly, infiltrates are found that upon immunostaining
consist of T cells only. Taynoud et al. studied such cases
from a clinical trial and were able to show that morphology
alone is not reliable in assessing these biopsies when
infiltrates are found and that, importantly, when infiltrates
consist of only T cells the patients have an improved
prognosis compared to patients without infiltrates. The
authors suggest that the T cell infiltrate might reflect a
beneficial immune response against lymphoma cells [37].
Kojima et al. reported on five cases they refer to as
idiopathic plasmacytic lymphadenopathy with polyclonal
hyperimmunoglobulinemia (IPL), all detected incidentally
on routine chest X-rays, with multiple small nodular lesions
in the bilateral lungs. Clinically, autoimmune disease was
suspected for all five cases, and the various autoantibodies
were investigated. Pathologically, all five lesions were
characterized by well-demarcated masses that consisted of
abundant reactive germinal centers and a dense lympho-
plasmacytic infiltrate in the interfollicular area with a
variable degree of interfollicular fibrosis. The immunohis-
tochemical study and PCR demonstrated the polytypic/
polyclonal nature of the plasma cells and B cells. It is
important to discriminate between pulmonary involvement
of IPL and marginal zone B cell lymphoma of the mucosa-
associated lymphoid tissue type [38].
Prognostic factors in lymphoma
Understanding lymphoma biology and using this knowl-
edge in clinical practice has for many years brought the
diagnosis of lymphomas at the forefront of diagnostic
pathology, using new technologies early on. This seems not
the case anymore since in contrast to solid tumors,
predictive factors are not rapidly replacing prognostic
factors in the lymphoma field (Her2/neu, KRAS, CD117),
with only CD20 as predicting rituximab response. Many
papers still appear that describe prognostic factors, but until
now, very few have come into clinical practice. Van Galen
et al. described that expression of tumor necrosis factor
receptor-associated factor 2 correlates with poor prognosis
in a group of 20 activated B cell-like-type diffuse large B
cell lymphoma but not in the 13 tested germinal center type
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[39]. LMO2 protein expression predicts survival in 263
patients with diffuse large B cell lymphoma treated with
anthracycline-based chemotherapy including those 80 that
had in addition rituximab [40].
In follicular lymphoma, germinal center-like diffuse
large B cell lymphoma, and HL, many FOXP3+ regulatory
T cells are associated with improved survival [41].
Martini et al. showed that expression of phosphorylated
STAT5 in cHL is associated with better survival compared
to negative cases [42].
For follicular lymphoma, a gene expression profile was
determined by Lebrun et al. that predicts poor outcome
[43]. Diaz-Alderete et al. showed that clinical features are
related to the presence of bcl2 and bcl6 translocations [44].
Using samples from 194 follicular lymphoma patients,
Cainioni showed that the poor prognostic impact of high
numbers of macrophages in patients treated without
rituximab disappears when rituximab is given [45].
It is well known that proliferation is an important
prognostic factor in mantle cell lymphoma. Using data
from a large clinical trail that used rituximab treatment,
Ki67 immunostaining remained prognostically relevant:
The three groups with different Ki67 index of less than
10%, 10% to less than 30%, and 30% or more showed
significantly different overall survival in patients treated
with CHOP as well as in patients treated with CHOP in
combination with anti-CD20 therapy [46].
D’Haene et al. showed that in 58 primary central
nervous system lymphomas, of the commonly observed
features necrosis, reactive perivascular T cell infiltrate and
endothelial hyperplasia, only the latter (present in 21% of
the cases) has a prognostic impact, but only in immune-
competent patients. Furthermore, endothelial galectin-3
expression but not galectin-1 expression indicated poor
prognosis, in immunocompetent cases only [47].
Patients with refractory celiac disease are prone to
develop enteropathy-associated T cell lymphomas. Verbeek
et al. show that the aberrant phenotype with a cutoff of 20%
as detected by flow cytometry predicts this development
better than clonality testing [48].
Staging
The group of Jong studied the staging and clinical data of 106
patients with primary extranodal nongastric marginal zone
MALT lymphoma. They confirm that this process frequently
presents as stage IV disease (26%) and multifocal disease
(32%) and with a site-specific dissemination pattern. They
proposed after an extensive staging procedure at presentation
to use primary site-directed protocols during follow-up
focused on the primary-involved tract/organ system, regional
lymph nodes, and pulmonary or gastric relapses [49].
Staging of lymphoma patients remains a cornerstone in
clinical management. Bone marrow involvement is often a
determining criterion but is not done optimally in many
cases. In a series of 113 cases of diffuse large B cell
lymphoma from one institution, Talaulikar et al. showed
that flow cytometry detected involvement in seven cases
that were negative by histology but also that 11 cases were
missed. Their results also show that combining the positive
cases from conventional staging and flow cytometry has
the best predictive value for survival. These data are
difficult to interpret, since staging has an influence on
treatment [50].
Increasingly fluorodeoxyglucose (FDG) positron emis-
sion tomography (PET) is being used in the staging
procedure of lymphoma patients. Pelosi et al. addressed
the question whether this technique can replace bone
marrow biopsies in 194 patients. Although PET and
biopsies had similar sensitivity and accuracy, bone marrow
involvement was identified by both methods in only 10 out
of 49 patients with positive bone marrow involvement by
either one of the techniques. There were no significant
differences between the HL and the non-HL patients. The
authors conclude that FDG-PET has added value to bone
marrow biopsies but does not replace them [51].
Ancillary techniques
Less invasive approaches for diagnosing and classifying
lymphomas are potentially very important. The proteomic
spectra of crude sera from 132 patients with diffuse large B
cell lymphoma and 75 controls obtained by surface-
enhanced laser desorption/ionization time-of-flight mass
spectrometry (SELDI-TOF-MS) achieved a sensitivity of
94% and a specificity of 94% for detecting diffuse large B
cell lymphoma samples in the test set of 85 samples and
achieved a sensitivity of 94% and a specificity of 92% for
detecting poor prognosis patients in the test set of 66
samples [52]. Using a similar SELDI-TOF-MS approach on
small biopsies/fine-needle aspirations from lymphoma
patients, Jansen et al. were able to create protein profiles that
separate reactive lymph nodes and low-grade B cell lympho-
mas from cases of diffuse large B cell lymphoma [53]. Using
liquid chromatography/mass spectrometry, Roy et al. ana-
lyzed the cerebrospinal fluid (CSF) from patients with
central nervous lymphoma and confirmed the results with
enzyme-linked immunosorbent assay. Approximately 80
CSF proteins were identified and found to be present at
significantly different concentrations, both higher and lower,
in training and test studies, which were highly concordant.
The findings demonstrate that proteomic analysis of CSF
yields individual biomarkers with greater sensitivity in the
identification of cancer than does CSF cytology [54].
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Lohan et al. went one step further and described the
magnetic resonance enterography results of ten patients with
small bowel lymphoma and provided features that enable the
prediction of the histological type of lymphoma [55].
Lymphoma classification is in some instances based on
cytogenetic data, but not many laboratories perform routine
cytogenetic analysis on biopsies for lymphoma. Dunphy and
Tang analyzed their experience with 261 samples, of which
four appeared to be nonhematologic malignancies. In 64
cases, no result was obtained. In 5 of 78 reactive neoplasias,
an abnormal cytogenetics was found, and three of these were
also clonal and developed follicular lymphoma soon after-
wards. Furthermore, in follicular lymphoma, additional
cytogenetic features were found to be related to more
aggressive grades. Finally, in several cases, the cytogenetic
data gave more insight in the process detected [56].
Flow cytometry is commonly used for leukemia classi-
fication but is increasingly used for lymphoma diagnosis in
conjunction with histological and immunohistochemical
evaluation. Karube et al. showed the value of this approach
in a series of 490 NK and T cell lymphoproliferations with
15 commonly used markers [57].
Clonality testing in skin lymphomas is considered of
little additional value because of the low specificity of the
test (Langerak et al.). This was confirmed by Plaza et al.
who used clonality testing of the T cell receptor beta gene
in a series of 80 cases with a cutaneous infiltrate including
reactive dermatoses. They confirmed that almost all cases
diagnosed as lymphoma were clonal but that also clonal
populations were present in some of the reactive dermato-
ses [58]. In an important study of Ponti et al., the multiple
biopsies approach proved helpful. In many patients, one has
more than one biopsy available, and it appeared that in
mycosis fungoides, an increase in clonality was observed in
connection with both a worsening of the cutaneous disease
(79% T1/T2; 100% T3/T4) and an increase in the
histopathologic score (HS<5, 76%; HS≥5, 94%) [59].
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